Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada, an Israeli biopharmaceutical company, has finalized its agreement with the Israeli Ministry of Health to become the exclusive manufacturer and supplier in Israel of snakebite antiserum against Vipera palaestinae and Echis coloratus.
Subscribe to our email newsletter
Under the terms of the agreement, the Israeli Ministry of Health will fund all costs associated with development of the antiserum and the establishment of a GMP manufacturing facility, a process which is expected to take two years.
During this period, Kamada will receive four payments from the Ministry of Health, totaling approximately $5 million. In addition, the Ministry of Health is committed to purchase antiserum for 10 years on agreed terms.
David Tsur, CEO of Kamada, said: “This is an important agreement for Kamada. Not only does it signal the Government’s confidence in our capabilities, it also allows us to strengthen our existing asset base. We look forward to working with the Israeli Ministry of Health in the development of snakebite antiserum and we hope that in the future our capabilities in this area will be recognized by others who require these niche products.”